134 related articles for article (PubMed ID: 38284189)
1. Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis.
Loras A; Gil-Barrachina M; Hernando B; Perez-Pastor G; Martinez-Domenech A; Mahiques L; Pitarch G; Valcuende-Cavero F; Ballester-Sanchez R; Marques-Torrejon MA; Martinez-Cadenas C
Exp Dermatol; 2024 Jan; 33(1):e15003. PubMed ID: 38284189
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
3. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
[TBL] [Abstract][Full Text] [Related]
4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.
Vasilopoulos Y; Manolika M; Zafiriou E; Sarafidou T; Bagiatis V; Krüger-Krasagaki S; Tosca A; Patsatsi A; Sotiriadis D; Mamuris Z; Roussaki-Schulze A
Mol Diagn Ther; 2012 Feb; 16(1):29-34. PubMed ID: 22111980
[TBL] [Abstract][Full Text] [Related]
7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
8. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
9. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
[TBL] [Abstract][Full Text] [Related]
10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
[TBL] [Abstract][Full Text] [Related]
12. HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.
Talamonti M; Galluzzo M; Zangrilli A; Papoutsaki M; Egan CG; Bavetta M; Tambone S; Fargnoli MC; Bianchi L
Mol Diagn Ther; 2017 Jun; 21(3):295-301. PubMed ID: 28130758
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles.
Hoffmann JHO; Knoop C; Schäkel K; Enk AH; Hadaschik EN
Acta Derm Venereol; 2021 May; 101(5):adv00462. PubMed ID: 33903917
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
[TBL] [Abstract][Full Text] [Related]
15. Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis.
Membrive-Jiménez C; Pérez-Ramírez C; Arias-Santiago S; Richetta AG; Ottini L; Pineda-Lancheros LE; Ramírez-Tortosa MDC; Jiménez-Morales A
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240048
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs.
Ovejero-Benito MC; Muñoz-Aceituno E; Sabador D; Almoguera B; Prieto-Pérez R; Hakonarson H; Coto-Segura P; Carretero G; Reolid A; Llamas-Velasco M; Abad-Santos F; Daudén E
Exp Dermatol; 2020 Dec; 29(12):1225-1232. PubMed ID: 33058233
[TBL] [Abstract][Full Text] [Related]
17. Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis.
Membrive Jiménez C; Pérez Ramírez C; Sánchez Martín A; Vieira Maroun S; Arias Santiago SA; Ramírez Tortosa MDC; Jiménez Morales A
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33921427
[TBL] [Abstract][Full Text] [Related]
18. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.
Loft ND; Skov L; Iversen L; Gniadecki R; Dam TN; Brandslund I; Hoffmann HJ; Andersen MR; Dessau RB; Bergmann AC; Andersen NM; Andersen PS; Bank S; Vogel U; Andersen V
Pharmacogenomics J; 2018 May; 18(3):494-500. PubMed ID: 28696418
[TBL] [Abstract][Full Text] [Related]
19. Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha -238 and -308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study.
Magalhães RF; Biral AC; Pancoto JA; Donadi EA; Mendes CT; Magna LA; Kraemer MH
Int J Dermatol; 2010 Oct; 49(10):1133-40. PubMed ID: 20931685
[TBL] [Abstract][Full Text] [Related]
20. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
